Q-omics provides the consensus-scored RBM41 profile across patient tissues and cancer cell-line models. RBM41 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RBM41 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RBM41 RNA expression shows 20,804 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SKCM, HNSC, and KIRP as cancer lineages where RBM41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM41 survival associations across molecular data types. RBM41 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM41 RNA expression–survival associations across cancer types. High RBM41 expression shows unfavorable associations in LGG, PAAD, COAD and KIRP, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RBM41 RNA expression.
This table summarizes RBM41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RBM41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM41 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, KIRC and CHOL. The HNSC box plot shows higher RBM41 RNA expression in tumor versus normal tissue (log2 FC = +1.214, t-test p < 0.001).
This table shows molecular features associated with RBM41 in patient tissues and cancer cell lines. In patient samples, RBM41 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BREAST.
